Search

Your search keyword '"Roussel M"' showing total 19 results
Start Over Author "Roussel M" Journal leukemia
19 results on '"Roussel M"'

2. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Author

Laubach, J, Garderet, L, Mahindra, A, Gahrton, G, Caers, J, Sezer, O, Voorhees, P, Leleu, X, Johnsen, H E, Streetly, M, Jurczyszyn, A, Ludwig, H, Mellqvist, U-H, Chng, W-J, Pilarski, L, Einsele, H, Hou, J, Turesson, I, Zamagni, E, Chim, C S, Mazumder, A, Westin, J, Lu, J, Reiman, T, Kristinsson, S, Joshua, D, Roussel, M, O'Gorman, P, Terpos, E, McCarthy, P, Dimopoulos, M, Moreau, P, Orlowski, R Z, Miguel, J S, Anderson, K C, Palumbo, A, Kumar, S, Rajkumar, V, Durie, B, and Richardson, P G

Published
2016
Full Text
View/download PDF

3. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Author

Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, and Avet-Loiseau, H

Published
2014
Full Text
View/download PDF

4. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL

Author

Garand, R, Beldjord, K, Cavé, H, Fossat, C, Arnoux, I, Asnafi, V, Bertrand, Y, Boulland, M-L, Brouzes, C, Clappier, E, Delabesse, E, Fest, T, Garnache-Ottou, F, Huguet, F, Jacob, M-C, Kuhlein, E, Marty-Grès, S, Plesa, A, Robillard, N, Roussel, M, Tkaczuk, J, Dombret, H, Macintyre, E, Ifrah, N, Béné, M C, and Baruchel, A

Published
2013
Full Text
View/download PDF

5. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Author

Leleu, X, Fouquet, G, Hebraud, B, Roussel, M, Caillot, D, Chrétien, M L, Arnulf, B, Szalat, R, Garderet, L, Benajiba, L, Pegourie, B, Regny, C, Royer, B, Caulier, A, Stoppa, A M, Garciaz, S, Touzeau, C, Chaleteix, C, Fermand, J P, Loiseau, H A, Facon, T, Attal, M, and Moreau, P

Published
2013
Full Text
View/download PDF

10. Erratum: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Author

Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, and Avet-Loiseau, H

Published
2014
Full Text
View/download PDF

11. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Author

Laubach, J, primary, Garderet, L, additional, Mahindra, A, additional, Gahrton, G, additional, Caers, J, additional, Sezer, O, additional, Voorhees, P, additional, Leleu, X, additional, Johnsen, H E, additional, Streetly, M, additional, Jurczyszyn, A, additional, Ludwig, H, additional, Mellqvist, U-H, additional, Chng, W-J, additional, Pilarski, L, additional, Einsele, H, additional, Hou, J, additional, Turesson, I, additional, Zamagni, E, additional, Chim, C S, additional, Mazumder, A, additional, Westin, J, additional, Lu, J, additional, Reiman, T, additional, Kristinsson, S, additional, Joshua, D, additional, Roussel, M, additional, O'Gorman, P, additional, Terpos, E, additional, McCarthy, P, additional, Dimopoulos, M, additional, Moreau, P, additional, Orlowski, R Z, additional, Miguel, J S, additional, Anderson, K C, additional, Palumbo, A, additional, Kumar, S, additional, Rajkumar, V, additional, Durie, B, additional, and Richardson, P G, additional

Published
2015
Full Text
View/download PDF

12. Cyclophosphamide as a first-line therapy in LGL leukemia

Author

Moignet, A, primary, Hasanali, Z, additional, Zambello, R, additional, Pavan, L, additional, Bareau, B, additional, Tournilhac, O, additional, Roussel, M, additional, Fest, T, additional, Awwad, A, additional, Baab, K, additional, Semenzato, G, additional, Houot, R, additional, Loughran, T P, additional, and Lamy, T, additional

Published
2013
Full Text
View/download PDF

13. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Author

Hebraud, B, primary, Leleu, X, additional, Lauwers-Cances, V, additional, Roussel, M, additional, Caillot, D, additional, Marit, G, additional, Karlin, L, additional, Hulin, C, additional, Gentil, C, additional, Guilhot, F, additional, Garderet, L, additional, Lamy, T, additional, Brechignac, S, additional, Pegourie, B, additional, Jaubert, J, additional, Dib, M, additional, Stoppa, A-M, additional, Sebban, C, additional, Fohrer, C, additional, Fontan, J, additional, Fruchart, C, additional, Macro, M, additional, Orsini-Piocelle, F, additional, Lepeu, G, additional, Sohn, C, additional, Corre, J, additional, Facon, T, additional, Moreau, P, additional, Attal, M, additional, and Avet-Loiseau, H, additional

Published
2013
Full Text
View/download PDF

14. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL

Author

Garand, R, primary, Beldjord, K, additional, Cavé, H, additional, Fossat, C, additional, Arnoux, I, additional, Asnafi, V, additional, Bertrand, Y, additional, Boulland, M-L, additional, Brouzes, C, additional, Clappier, E, additional, Delabesse, E, additional, Fest, T, additional, Garnache-Ottou, F, additional, Huguet, F, additional, Jacob, M-C, additional, Kuhlein, E, additional, Marty-Grès, S, additional, Plesa, A, additional, Robillard, N, additional, Roussel, M, additional, Tkaczuk, J, additional, Dombret, H, additional, Macintyre, E, additional, Ifrah, N, additional, Béné, M C, additional, and Baruchel, A, additional

Published
2012
Full Text
View/download PDF

15. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

Author

Avet-Loiseau, H, primary, Roussel, M, additional, Campion, L, additional, Leleu, X, additional, Marit, G, additional, Jardel, H, additional, Dib, M, additional, Decaux, O, additional, Lamy, T, additional, Tiab, M, additional, Cony-Makhoul, P, additional, Banos, A, additional, Lepeu, G, additional, Lifermann, F, additional, Macro, M, additional, Kolb, B, additional, Hulin, C, additional, Caillot, D, additional, Traulle, C, additional, Mathiot, C, additional, and Royer, B, additional

Published
2011
Full Text
View/download PDF

17. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Author

Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, and Leleu X

Subjects
Aged, Antineoplastic Agents adverse effects, Humans, Maintenance Chemotherapy, Multiple Myeloma diagnosis, Oligopeptides adverse effects, Progression-Free Survival, Antineoplastic Agents therapeutic use, Multiple Myeloma drug therapy, Oligopeptides therapeutic use
Published
2022
Full Text
View/download PDF

18. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Author

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, and Facon T

Subjects
Humans, Infection Control, Logistic Models, Multiple Myeloma drug therapy, Risk Factors, Infections etiology, Multiple Myeloma complications
Abstract

Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade ≥ 3 infection. The number of TE infections/month was highest during the first 4 months of treatment (defined as early infection). Of 1613 treated patients, 340 (21.1%) experienced TE grade ≥ 3 infections in the first 18 months and 56.2% of these patients experienced their first grade ≥ 3 infection in the first 4 months. Risk of early infection was similar regardless of treatment. Based on the analyses of data in 1378 patients through multivariate logistic regression, a predictive model of first TE grade ≥ 3 infection in the first 4 months retained Eastern Cooperative Oncology Group performance status and serum β 2 -microglobulin, lactate dehydrogenase, and hemoglobin levels to define high- and low-risk groups showing significantly different rates of infection (24.0% vs. 7.0%, respectively; P < 0.0001). The predictive model was validated with data from three clinical trials. This predictive model of early TE grade ≥ 3 infection may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention.

Published
2018
Full Text
View/download PDF

19. Cyclophosphamide as a first-line therapy in LGL leukemia.

Author

Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, and Lamy T

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Antineoplastic Agents, Alkylating therapeutic use, Cyclophosphamide therapeutic use, Leukemia, Large Granular Lymphocytic drug therapy
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results